Table of Contents
ISRN Pulmonology
Volume 2013 (2013), Article ID 582807, 11 pages
http://dx.doi.org/10.1155/2013/582807
Review Article

Pharmacotherapy of Chronic Obstructive Pulmonary Disease: A Clinical Review

1Department of Pathophysiology, National Koranyi Institute of TB and Pulmonology, Piheno ut 1, Budapest 1121, Hungary
2Department of Pulmonology, National Koranyi Institute of TB and Pulmonology, Piheno ut 1, Budapest 1121, Hungary

Received 11 January 2013; Accepted 7 February 2013

Academic Editors: A. Celi, A. Kurdowska, A. Miyazato, and A. Yokoyama

Copyright © 2013 Balazs Antus. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. D. Lopez, K. Shibuya, C. Rao et al., “Chronic obstructive pulmonary disease: current burden and future projections,” European Respiratory Journal, vol. 27, no. 2, pp. 397–412, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. D. M. Mannino and A. S. Buist, “Global burden of COPD: risk factors, prevalence, and future trends,” The Lancet, vol. 370, no. 9589, pp. 765–773, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Nielsen, A. Johannessen, B. Benediktsdottir et al., “Present and future costs of COPD in Iceland and Norway: results from the BOLD study,” European Respiratory Journal, vol. 34, no. 4, pp. 850–857, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. D. Sullivan, S. D. Ramsey, and T. A. Lee, “The economic burden of COPD,” Chest, vol. 117, no. 2, 2000. View at Google Scholar · View at Scopus
  5. C. D. Mathers and D. Loncar, “Projections of global mortality and burden of disease from 2002 to 2030,” PLoS Medicine, vol. 3, no. 11, article e442, pp. 2011–2030, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. P. D. Scanlon, J. E. Connett, L. A. Waller et al., “Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the lung health study,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 2, pp. 381–390, 2000. View at Google Scholar · View at Scopus
  7. P. M. A. Calverley, J. A. Anderson, B. Celli et al., “Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 356, no. 8, pp. 775–789, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Decramer, B. Celli, S. Kesten, T. Lystig, S. Mehra, and D. P. Tashkin, “Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial,” The Lancet, vol. 374, no. 9696, pp. 1171–1178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Cazzola and R. Dahl, “Inhaled combination therapy with long-acting β2-agonists and corticosteroids in stable COPD,” Chest, vol. 126, no. 1, pp. 220–237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. P. M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, and H. Olsson, “Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease,” European Respiratory Journal, vol. 22, no. 6, pp. 912–919, 2003. View at Google Scholar
  11. “Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease,” http://www.goldcopd.com/.
  12. B. P. Yawn, G. L. Colice, and R. Hodder, “Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 7, pp. 495–502, 2012. View at Google Scholar
  13. R. A. M. Al-Showair, W. Y. Tarsin, K. H. Assi, S. B. Pearson, and H. Chrystyn, “Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?” Respiratory Medicine, vol. 101, no. 11, pp. 2395–2401, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Papi, M. Romagnoli, S. Baraldo et al., “Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 5, pp. 1773–1777, 2000. View at Google Scholar · View at Scopus
  15. http://www.drugbank.ca/.
  16. R. Bone, M. Boyars, S. R. Braun et al., “In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial,” Chest, vol. 105, no. 5, pp. 1411–1419, 1994. View at Google Scholar · View at Scopus
  17. A. Rossi, P. Kristufek, B. E. Levine et al., “Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD,” Chest, vol. 121, no. 4, pp. 1058–1069, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Boyd, A. H. Morice, J. C. Pounsford, M. Siebert, N. Peslis, and C. Crawford, “An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD),” European Respiratory Journal, vol. 10, no. 4, pp. 815–821, 1997. View at Google Scholar
  19. M. Campbell, A. Eliraz, G. Johansson et al., “Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 99, no. 12, pp. 1511–1520, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. D. A. Mahler, J. F. Donohue, R. A. Barbee et al., “Efficacy of salmeterol xinafoate in the treatment of COPD,” Chest, vol. 115, no. 4, pp. 957–965, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Dahl, K. F. Chung, R. Buhl et al., “Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD,” Thorax, vol. 65, no. 6, pp. 473–479, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. P. J. Barnes, “The role of anticholinergics in chronic obstructive pulmonary disease,” The American Journal of Medicine, vol. 117, pp. 24S–32S, 2004. View at Google Scholar · View at Scopus
  23. A. M. Yohannes, T. G. Willgoss, and J. Vestbo, “Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes,” Respiratory Care, vol. 56, no. 4, pp. 477–487, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Brusasco, R. Hodder, M. Miravitlles, L. Korducki, L. Towse, and S. Kesten, “Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD,” Thorax, vol. 58, no. 5, pp. 399–404, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. D. D. Briggs Jr., H. Covelli, R. Lapidus, S. Bhattycharya, S. Kesten, and C. Cassino, “Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD,” Pulmonary Pharmacology and Therapeutics, vol. 18, no. 6, pp. 397–404, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Wedzicha, P. M. A. Calverley, T. A. Seemungal, G. Hagan, Z. Ansari, and R. A. Stockley, “The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 1, pp. 19–26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Casaburi, D. Kukafka, C. B. Cooper, T. J. Witek, and S. Kesten, “Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD,” Chest, vol. 127, no. 3, pp. 809–817, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Singh, Y. K. Loke, and C. D. Furberg, “Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis,” Journal of the American Medical Association, vol. 300, no. 12, pp. 1439–1450, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. D. P. Tashkin, B. Celli, S. Senn et al., “A 4-year trial of tiotropium in chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 359, pp. 1543–1554, 2008. View at Publisher · View at Google Scholar
  30. T. M. Michele, S. Pinheiro, and S. Iyasu, “The safety of tiotropium—the FDA's conclusions,” The New England Journal of Medicine, vol. 363, no. 12, pp. 1097–1099, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Auerbach, C. Hill, R. Baughman et al., “Routine nebulized ipratropium and albuterol together are better than either alone in COPD,” Chest, vol. 112, no. 6, pp. 1514–1521, 1997. View at Google Scholar · View at Scopus
  32. J. A. van Noord, J. L. Aumann, E. Janssens et al., “Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD,” European Respiratory Journal, vol. 26, no. 2, pp. 214–222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. S. E. McKay, C. A. Howie, A. H. Thomson, B. Whiting, and G. J. Addis, “Value of theophylline treatment in patients handicapped by chronic obstructive lung disease,” Thorax, vol. 48, no. 3, pp. 227–232, 1993. View at Google Scholar · View at Scopus
  34. M. Aubier, “Respiratory muscle pharmacotherapy,” European Respiratory Journal, vol. 7, pp. 592S–594S, 1989. View at Google Scholar
  35. Y. To, K. Ito, Y. Kizawa et al., “Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 7, pp. 897–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Zhou, X. Wang, X. Zeng et al., “Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year,” Respirology, vol. 11, no. 5, pp. 603–610, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Cazzola and R. Dahl, “Inhaled combination therapy with long-acting β2-agonists and corticosteroids in stable COPD,” Chest, vol. 126, no. 1, pp. 220–237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. P. M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, and S. Peterson, “Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease,” European Respiratory Journal, vol. 22, no. 6, pp. 912–919, 2003. View at Google Scholar
  39. C. Crim, P. M. A. Calverley, J. A. Anderson et al., “Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results,” European Respiratory Journal, vol. 34, no. 3, pp. 641–647, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Singh, J. Brooks, G. Hagan, A. Cahn, and B. J. O'Connor, “Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD,” Thorax, vol. 63, no. 7, pp. 592–598, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Welte, M. Miravitlles, P. Hernandez et al., “Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 8, pp. 741–750, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. B. J. Lipworth, “Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease,” The Lancet, vol. 365, no. 9454, pp. 167–175, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Price, A. Chisholm, D. Ryan, A. Crockett, and R. Jones, “The use of roflumilast in COPD: a primary care perspective,” Primary Care Respiratory Journal, vol. 19, no. 4, pp. 342–351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. P. M. Calverley, K. F. Rabe, U. M. Goehring, S. Kristiansen, L. M. Fabbri, and F. J. Martinez, “Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials,” The Lancet, vol. 374, no. 9691, pp. 685–694, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. K. F. Rabe, E. D. Bateman, D. O'Donnell, S. Witte, D. Bredenbröker, and T. D. Bethke, “Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial,” The Lancet, vol. 366, no. 9485, pp. 563–571, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. C. H. Compton, J. Gubb, R. Nieman et al., “Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study,” The Lancet, vol. 358, no. 9278, pp. 265–270, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. M. A. Giembycz, “An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease,” British Journal of Clinical Pharmacology, vol. 62, no. 2, pp. 138–152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. M. A. Giembycz, “Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease,” Expert Opinion on Investigational Drugs, vol. 10, no. 7, pp. 1361–1379, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. J. R. Jacobsen, “Third-generation long-acting β2-adrenoceptor agonists: medicinal chemistry strategies employed in the identification of once-daily inhaled β2-adrenoceptor agonists,” Future Medicinal Chemistry, vol. 3, no. 13, pp. 1607–1622, 2011. View at Publisher · View at Google Scholar
  50. D. P. Tashkin and L. M. Fabbri, “Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents,” Respiratory Research, vol. 11, article 149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. D. L. Kelleher, R. S. Mehta, B. M. Jean-Francois et al., “Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial,” PLoS One, vol. 7, Article ID e50716, 2012. View at Publisher · View at Google Scholar
  52. N. A. Hanania, G. Feldman, W. Zachgo et al., “The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial,” Chest, vol. 142, pp. 119–127, 2012. View at Publisher · View at Google Scholar
  53. G. Feldman, R. R. Walker, J. Brooks, R. Mehta, and G. Crater, “28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial,” Pulmonary Pharmacology & Therapeutics, vol. 25, pp. 465–471, 2012. View at Publisher · View at Google Scholar
  54. W. W. Busse, E. R. Bleecker, E. D. Bateman et al., “Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial,” Thorax, vol. 67, pp. 35–41, 2012. View at Publisher · View at Google Scholar
  55. J. A. van Noord, J. J. Smeets, B. M. Drenth et al., “24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD,” Pulmonary Pharmacology & Therapeutics, vol. 24, pp. 666–672, 2011. View at Publisher · View at Google Scholar
  56. V. Gupta and D. Singh, “Aclidinium bromide for the treatment of chronic obstructive pulmonary disease,” Expert Review of Respiratory Medicine, vol. 6, pp. 581–588, 2012. View at Publisher · View at Google Scholar
  57. M. W. Sims and R. A. Panettieri Jr., “Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 6, pp. 457–466, 2011. View at Google Scholar
  58. P. Chanez, P. S. Burge, R. Dahl et al., “Aclidinium bromide provides long-acting bronchodilation in patients with COPD,” Pulmonary Pharmacology and Therapeutics, vol. 23, no. 1, pp. 15–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. P. W. Jones, D. Singh, E. D. Bateman et al., “Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study,” European Respiratory Journal, vol. 40, pp. 830–836, 2012. View at Publisher · View at Google Scholar
  60. R. Fuhr, H. Magnussen, K. Sarem et al., “Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD,” Chest, vol. 141, no. 3, pp. 745–752, 2012. View at Publisher · View at Google Scholar
  61. F. Maltais, B. Celli, R. Casaburi et al., “Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD,” Respiratory Medicine, vol. 105, no. 4, pp. 580–587, 2011. View at Publisher · View at Google Scholar · View at Scopus